Table 2.
Multivariable Analysis for Clinical Outcome.
| Variables | OS | Relapse | NRM | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Sex, female (ref. female) | 3 (1–7) | 0.02 | NA | NA | 8 (1–74) | 0.08 |
| Age, ＞35 years (ref. ≤35) | NA | NA | 1 (0.5–4) | 0.58 | NA | NA |
| T-ALL (ref. T-LBL) | 2 (1–3) | 0.25 | NA | NA | NA | NA |
| LDH Elevated (ref. Normal) | NA | NA | 2 (1–5) | 0.11 | NA | NA |
| Disease status at allo-HCT, Non-CR (ref. CR) | NA | NA | 2 (1–5) | 0.12 | NA | NA |
| HCI-CI | ||||||
| 0 (ref.) | 1 | 1 | 1 | |||
| 1 | 1 (1–3) | 0.64 | 2 (1–4) | 0.35 | 1 (0.2–3) | 0.85 |
| ≥2 | 4 (1–14) | 0.011 | 3 (0.5–18) | 0.20 | 6 (0.5–66) | 0.17 |
| Median months from diagnosis to HCT, ≥7 (ref. ＜7) | 3 (1–8) | 0.034 | NA | NA | NA | NA |
| Conditioning regimen | ||||||
| BU/CY(ref.) | 1 | 1 | 1 | |||
| TBI/CY | 1 (0.4–2) | 0.82 | 1 (0.34–3) | 0.99 | 0.3 (0.1–2) | 0.23 |
| BU/Flu | 35 (6–213) | 0.001 | 10 (1 -80) | 0.03 | 18 (1–253) | 0.03 |
OS, overall survival; NRM, non-relapse mortality; T-ALL, T-cell acute lymphoblastic leukemia; T-LBL, T-cell lymphoblastic lymphoma; allo-HCT, allogeneic hematopoietic cell transplantation; ETP, early-thymic precursor; MRD, measurable residual disease; HCI-CI, hematopoietic cell transplantation comorbidity index; MSD, HLA-matched sibling donors; Haploidentical, HLA-haploidentical donors; MUD, HLA-matched unrelated donors; TBI/CY, total body irradiation/cyclophosphamide; BU/CY, busulfan/cyclophosphamide.